These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30655068)

  • 1. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery.
    Barbetta A; Sihag S; Nobel T; Hsu M; Tan KS; Bains M; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2019 Mar; 157(3):1249-1259.e5. PubMed ID: 30655068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery.
    Wu YY; Dai L; Yang YB; Yan WP; Cheng H; Fan MY; Gao YM; Chen KN
    Ann Surg Oncol; 2024 Aug; 31(8):5047-5054. PubMed ID: 38172446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of recurrent disease after neoadjuvant chemoradiotherapy and esophageal cancer surgery with curative intent in a tertiary referral center.
    Schuring N; Stam WT; Plat VD; Kalff MC; Hulshof MCCM; van Laarhoven HWM; Derks S; van der Peet DL; van Berge Henegouwen MI; Daams F; Gisbertz SS
    Eur J Surg Oncol; 2023 Oct; 49(10):106947. PubMed ID: 37355392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
    Lee J; Kim HK; Park BJ; Cho JH; Choi YS; Zo JI; Shim YM; Pyo H; Ahn YC; Ahn JS; Ahn MJ; Park K; Kim J
    Lung Cancer; 2018 Jan; 115():89-96. PubMed ID: 29290268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes.
    Xi M; Yang Y; Zhang L; Yang H; Merrell KW; Hallemeier CL; Shen RK; Haddock MG; Hofstetter WL; Maru DM; Ho L; Wu CC; Liu M; Lin SH
    Ann Surg; 2019 Apr; 269(4):663-670. PubMed ID: 29334555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Nagata Y; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Surgery; 2018 Mar; ():. PubMed ID: 29519558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
    Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
    Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.
    Chen D; Kong M; Sun J; Yang H; Chen Y; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Witharana P; Fu J; Chen B; Shen J; Zhu C
    J Thorac Cardiovasc Surg; 2023 Mar; 165(3):888-897. PubMed ID: 36137841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.
    Yang J; Huang A; Yang K; Jiang K
    BMC Cancer; 2023 Mar; 23(1):249. PubMed ID: 36922805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy.
    Zhou Y; He W; Guo P; Zhou C; Luo M; Liu Y; Yang H; Qin S; Leng X; Huang Z; Liu Y
    Ann Surg Oncol; 2024 Jan; 31(1):178-191. PubMed ID: 37751117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies.
    Zhou S; Liu S; Zhang L; Guo S; Shen J; Li Q; Yang H; Feng Y; Liu M; Lin SH; Xi M
    Ann Surg Oncol; 2018 Nov; 25(12):3639-3646. PubMed ID: 30194608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.
    Blackham AU; H Naqvi SM; Schell MJ; Jin W; Gangi A; Almhanna K; Fontaine JP; Hoffe SE; Frakes J; Venkat P; Pimiento JM
    J Surg Oncol; 2018 Feb; 117(2):150-159. PubMed ID: 28833197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy.
    Liw PX; Wen YW; Tsai CY; Chang HK; Tseng CK; Hung TM; Chao YK
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2233-2242.e2. PubMed ID: 29397973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
    Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma.
    Ogawa K; Ishikawa H; Hisakura K; Hiroshima Y; Moriwaki T; Yamada T; Yamamoto Y; Akashi Y; Owada Y; Ohara Y; Enomoto T; Furuya K; Doi M; Shimomura O; Takahashi K; Hashimoto S; Sakurai H; Oda T
    Int J Clin Oncol; 2021 Oct; 26(10):1856-1863. PubMed ID: 34241725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
    Kim MK; Cho KJ; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Song HJ; Ryu JS; Kim SB
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):115-21. PubMed ID: 19251379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.